Sponsored content
Occasionally I come across stock ideas from people in my network that I want to share with you.
Sometimes they look overpriced to me, or they just don't fit the criteria I look for, so I pass on mentioning them to you.
But when I started looking into Avalon GloboCare Corp (ALBT), I knew it was something I had to share with you!
Trading near the lower-end of the recent range at just $3, I think ALBT is definitely something that you might find interesting.
Especially when you look at the price chart over the last few months and see the potential ALBT has actually had for major moves:
Even Yahoo Finance is full-blown bullish with short-term trading indicators right now…
ALBT recently announced that it has deployed a breakthrough "fusion gene map technology" to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.
Their CEO said, "Fusion genes are crucial in the diagnosis and treatment of leukemia. All well-known fusion genes are founder variations and constitute critical causative factors and can serve as important indicators of disease diagnosis," (1)
Also, ALBT has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leading education and research center in Europe, as well as a premier multi-national developer of cellular therapies in the field of oncology. (2)
On Seeking Alpha, I read they recently announced a warrant buyback program. They reported, "ALBT announced on October 21 that the company plans to repurchase all of the 1.7M outstanding warrants for approximately $1.4M. Of note, the warrants were issued to institutional investors in a direct offering back on April 25 this year. Looking ahead, the warrant repurchase will be completed by November 8. At that time, all of the outstanding warrants will be canceled." (3)
Canceling warrants sounds like a great move to me, as that would limit the amount of future dilution from shareholders if the stock makes a big move up.
Seeking Alpha also seems pretty bullish on the stock too. As a tiny, $3 stock, there aren't a lot of articles about it, but these were very bullish when I read them…
One of the more interesting pieces I read talked about a new definitive agreement ALBT has to acquire a lab with a sizeable footprint. This sounds like a great move for a small therapeutics company.
The article said, "ALBT signed a definitive agreement to acquire a 60% interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25M, net income in excess of $10M, and over 600,000 tests completed since inception." (3)
You can read the full article from this page.
And it just keeps going!
On TipRanks, I wanted to see what their technical outlook was and sure enough, they are rating it very favorably right now too…
(4)
I just see "buy ratings" across the board. Maybe they know something?...
Looking into the market for ALBT, the company has some pretty impressive numbers to share on that. They reported that the global leukemia therapeutics market is expected to grow from $13.88 billion in 2021 to $15.27 billion in 2022 at a compound annual growth rate (CAGR) of 10.07%. The leukemia therapeutics market is expected to reach $20.77 billion in 2026 at a CAGR of 7.99% (5)
And finally, I grabbed some information about the odds of future moves from Tickeron (of course, you can never predict with certainty where a stock will go, I just wanted to see how things have performed historically).
Their data shows that the Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 61 cases where ALBT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend: 87%.
The Moving Average Convergence Divergence (MACD) for ALBT just turned positive on February 03, 2023. Looking at past instances where ALBT's MACD turned positive, the stock continued to rise in 39 of 43 cases over the following month. The odds of a continued upward trend: 90%
Following a +8.55% 3-day advance, the price is estimated to grow further. Considering data from situations where ALBT advanced for three days, in 175 of 212 cases, the price rose further within the following month. The odds of a continued upward trend: 83%
I was pretty blown away by the potential for ALBT after doing my homework this weekend.
For a $3 stock that is trading near key-support levels and has a history of major advances, I think this is definitely a stock you should be watching this week.
I hope you do your own homework this week and let me know what you think about ALBT?
Take care!
Source:https://finance.yahoo.com/news/avalon-globocare-announces-deployment-breakthrough-140000864.html
Source: https://finance.yahoo.com/news/avalon-globocare-expands-ip-portfolio-130000830.html
Source:https://seekingalpha.com/article/4306638-avalon-fortressing-capital-structure-and-strengthening-fundamentals
Source: https://www.tipranks.com/stocks/albt/technical-analysis
Source: https://www.businesswire.com/news/home/20220912005443/en/Leukemia-Therapeutics-Global-Market-Report-2022-A-20-Billion-Market-in-2026
Source: https://tickeron.com/ticker/ALBT/
Jason Bond
Post a Comment
Post a Comment